Bluebird sets $1.8M price tag for blood-disease gene therapy

Bluebird Bio announced it has set a price of 1.6 million euros ($1.8 million) for gene therapy Zynteglo, which so far has only been approved for a rare blood disorder in the European Union. The cost will be spread over five years based on its continued effectiveness, at 315,000 euros a year.